- |||||||||| Avastin (bevacizumab) / Roche, IBI-323 / Innovent Biologics, Alecensa (alectinib) / Roche
Biomarker, Enrollment open, Trial completion date, Trial primary completion date: Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov) - Dec 27, 2023 P2, N=70, Recruiting, Trial completion date: Nov 2023 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Dec 2024 Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- |||||||||| IBI-363 / Innovent Biologics
Enrollment open, Metastases: Promise: The Efficacy and Safety of IBI363 in Solid Tumors (clinicaltrials.gov) - Dec 27, 2023 P1, N=430, Recruiting, Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Not yet recruiting --> Recruiting
- |||||||||| JS201 / Shanghai Junshi Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (clinicaltrials.gov) - Dec 27, 2023 P2, N=30, Recruiting, Not yet recruiting --> Recruiting Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2024
- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Impact of body mass index on the prognosis of unresectable HCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab (ePoster Area) - Dec 26, 2023 - Abstract #LCS2024LCS_56; This data emphasizes the importance of establishing hospital networks for early detection and ensuring timely access to experienced specialists for the management of immune related adverse events. Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received Atezolizumab plus Bevacizumab, while no prognostic role for low BMI was apparent in patients who received Lenvatinib.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Safety and efficacy of lenvatinib in very elderly patients with unresectable hepatocellular carcinoma (ePoster Area) - Dec 26, 2023 - Abstract #LCS2024LCS_32; Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received Atezolizumab plus Bevacizumab, while no prognostic role for low BMI was apparent in patients who received Lenvatinib. Our study highlights the same efficacy and safety of Lenvatinib between elderly and not elderly patients
- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Evaluation of glycemia and diabetes as prognostic factors in advanced hepatocellular carcinoma treated with systemic therapy (ePoster Area) - Dec 26, 2023 - Abstract #LCS2024LCS_19; Our study suggests the lack of an association between hyperglycemia and/or DM and OS among aHCC patients who undergo ST, which is not hampered by coexistent DM/hyperglycemia. Other laboratory findings universally available in clinical practice, such as ALT levels and NLR, were associated with poorer prognosis in the study population
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date: PULSAR: Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma (clinicaltrials.gov) - Dec 18, 2023 P2, N=25, Not yet recruiting, Phase classification: P1b/2 --> P1/2 Trial completion date: Mar 2029 --> Feb 2030 | Initiation date: Jun 2023 --> Feb 2024 | Trial primary completion date: Mar 2028 --> Feb 2029
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Checkpoint inhibition, Checkpoint block: Near-Infrared-II Nanoparticles for Vascular Normalization Combined with Immune Checkpoint Blockade via Photodynamic Immunotherapy Inhibit Uveal Melanoma Growth and Metastasis. (Pubmed Central) - Dec 18, 2023 In this study, a novel nanoparticle denoted as Combo-NP is introduced, composed of a biodegradable NIR II fluorescent pseudo-conjugate polymer featuring disulfide bonds within its main chain, designated as TPA-BD, and the vascular inhibitor Lenvatinib...Furthermore, when combined with anti-programmed death-ligand 1 (PD-L1), they showcase notable inhibitory effects on tumor metastasis. The findings in this study introduce an innovative nanomedicine strategy aimed at triggering systemic anti-tumor immune responses for the treatment of Uveal melanoma.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib. (Pubmed Central) - Dec 17, 2023 Before administration of lenvatinib, 57.1% of the HBV-HCC patients and 88.4% of the HCV-HCC patients had well-controlled viremia, and their PFS (8.8 vs. 3.1?months, p?<?0.001) and OS (30.2 vs. 12.8?months, p?=?0.041) were better than those who had uncontrolled viremia; moreover, well-controlled viremia reduced tumor progression in multivariate analysis (Hazard ratio: 0.41, 95% confidence interval: 0.25-0.68, p?=?0.001) after adjusting for albumin-bilirubin grade and concurrent treatment. HBV or HCV infection was not associated with tumor progression of HCC patients receiving lenvatinib, but viremia, controlled or not, was.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC). (Level 1, West Hall; Poster Bd # L1) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_825; Background: The CLEAR trial showed statistically significant improvements in overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and complete response (CR) in subjects treated with lenvatinib plus pembrolizumab (L+P) vs. sunitinib...For PFS (assessed under United States Food and Drug Administration censoring rules), L+P showed a >75% probability of providing greater benefit over all available comparators, including numerical, but not statistically significant advantage over immunoncology (IO) therapies nivolumab+ipilimumab (N+I), avelumab+axitinib (A+A), nivolumab+cabozantinib (N+C) and pembrolizumab + axitinib (P+A). The benefit was significant for 13 out of 18 comparators
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN+PEM). (Level 1, West Hall; Poster Bd # H15) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_776; P1b/2 In the CLEAR study, it produced a 71% objective response rate (ORR), an 18% complete response rate, and improved progression-free survival (PFS) and overall survival (OS) compared to sunitinib... In this cohort of heavily pretreated pts who received CABO after LEN+PEM, CABO demonstrated a modest clinical benefit in a minority of pts, underscoring the need to develop effective novel therapies for aRCC.
- |||||||||| Health-related quality of life (HrQoL) of first-line treatments in metastatic renal cell carcinoma (mRCC): A network meta-analysis. (Level 1, West Hall; Poster Bd # G15) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_755;
Global QoL was significantly improved with cabozantinib-nivolumab (CaboNivo) as compared to Nivo-ipilimumab (SMD 2.74, 95% CI 2.54; 2.93), lenvatinib-pembrolizumab (LenPem; 2.79, 2.53; 3.06), sunitinib (2.87, 2.72; 3.03), Pem-axitinib (PemAxi; 3.09, 2.89; 3.30) and atezolizumab-bevacizumab (AteBev; 3.24, 3.04; 3.45)... CaboNivo and NivoIpi as 1L therapy may offer an improved overall HrQoL compared to other contemporary treatment options in mRCC.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Real world data on treatment of chromophobe renal cell carcinoma. (Level 1, West Hall; Poster Bd # G12) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_753; No standardized treatment for metastatic disease could be identified. Overall treatment duration was comparable to clear cell carcinoma.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
First-line pembrolizumab plus lenvatinib for non (Level 1, West Hall; Poster Bd # E1) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_699; P2 These results continue to support pembro + lenva as a first-line treatment option for pts with variant histologies of nccRCC. Clinical trial information: NCT04704219.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade. (Level 1, West Hall; Poster Bd # M18) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_694; Exploratory analyses will include evaluation of tissue, blood-based and cerebrospinal fluid immune-related correlates, identification of imaging characteristics of treatment, evaluation of the neurological and cognitive function, seizure reduction, steroid, and opiate pain medication. Clinical trial information: N/A.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial. (Level 3, Ballroom) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_162; P3 Clinical Trial Registration Number: NCT02811861 Sponsored by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Background: In the primary analysis of the phase 3 open-label CLEAR trial, lenvatinib + pembrolizumab (L+P) showed statistically significant and clinically meaningful improvements in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) compared with sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) (Motzer NEJM 2021)... 1069 treatment-na
|